Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM(SM) registry

BACKGROUND: Prognostic scoring systems are used to estimate the risk of mortality from metastatic renal cell carcinoma (mRCC). Outcomes from different therapies may vary within each risk group. These survival algorithms have been applied to assess outcomes in patients receiving T-cell checkpoint inh...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Immunother Cancer
Main Authors: Fishman, M., Dutcher, J. P., Clark, J. I., Alva, A., Miletello, G. P., Curti, B., Agarwal, Neeraj, Hauke, R., Mahoney, K. M., Moon, H., Treisman, J., Tykodi, S. S., Daniels, G., Morse, M. A., Wong, M. K. K., Kaufman, H., Gregory, N., McDermott, D. F.
Format: Artigo
Sprog:Inglês
Udgivet: BioMed Central 2019
Fag:
Research Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6437874/
https://ncbi.nlm.nih.gov/pubmed/30917871
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0567-3
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker